Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.

Despite the challenges, Novo Nordisk plans to submit CagriSema for regulatory approval in obesity in the first quarter of 2026.

June 22 (Reuters) - Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other ...

CagriSema delivers significant weight loss: In the REDEFINE 1 trial, Novo Nordisk’s CagriSema achieved a 22.7% mean weight reduction in adults with obesity or overweight without diabetes. Over half ...

(RTTNews) - Novo Nordisk's (NVO) Phase 3 REDEFINE 1 trial found that treatment with CagriSema led to a 22.7% weight loss at 68 weeks among patients who adhered to the treatment, compared to 2.3% ...

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new late-stage results for CagriSema.

About CagriSema Once-weekly subcutaneous CagriSema is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with ...

Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as it tries to reassure the market of its potential after disappointing ...

COPENHAGEN (Reuters) -Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as it tries to reassure the market of its potential ...

COPENHAGEN (Reuters) -Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as it tries to reassure the market of its potential after ...